Roth Capital Initiates Coverage on Recro Pharma Inc to Buy

Roth Capital Initiates Coverage on Recro Pharma Inc(NASDAQ:REPH). The shares have been rated Buy. The rating by Roth Capital was issued on Sep 16, 2016.

In a different note, Janney Capital said it Initiates Coverage on Recro Pharma Inc, according to a research note issued on Aug 29, 2016. The shares have been rated ‘Buy’ by the firm.

Recro Pharma Inc (REPH) shares turned negative on Thursdays trading session with the shares closing down -0.16 points or -1.71% at a volume of 23,326. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.45. The peak price level was also seen at $9.45 while the days lowest was $9.16. Finally the shares closed at $9.18. The 52-week high of the shares is $17.1892 while the 52-week low is $5.59. According to the latest information available, the market cap of the company is $91 M.

Recro Pharma Inc(REPH) last announced its earnings results on Aug 11, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $17.28M. Analysts had an estimated revenue of $15.43M. Earnings per share were $-0.83. Analysts had estimated an EPS of $-0.78.

Several Insider Transactions has been reported to the SEC. On Jun 2, 2016, Fred Graff (Chief Commercial Officer) purchased 8,000 shares at $8.46 per share price.Also, On May 31, 2016, Stewart Mccallum (Chief Medical Officer) purchased 1,250 shares at $8.32 per share price.On May 25, 2016, Randall Mack (Senior VP, Development) purchased 2,000 shares at $6.30 per share price, according to the Form-4 filing with the securities and exchange commission.

Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *